# 人狂犬病疫苗市场 > 人狂犬病疫苗市场研究报告按疫苗类型（灭活病毒疫苗、减毒活病毒疫苗、重组疫苗）、给药途径（肌肉注射、皮内注射、皮下注射）、免疫球蛋白（人狂犬病免疫球蛋白（HRIG）、马狂犬病免疫球蛋白（ERIG））、应用（预防接种、暴露后预防）、剂型（小瓶、预填充注射器）以及按地区（北美、欧洲、南美、亚太、中东和非洲）- 预测到2035年 - **Forecast Period:** 2025 - 2035 - **CAGR:** 6.98% - **2024:** $ 0.62 Billion - **2025:** $ 0.67 Billion - **2035:** $ 1.31 Billion - **Key Players:** Companies such as Sanofi(FR), Bharat Biotech (IN), Merck & Co. (US), GlaxoSmithKline (GB), Serum Institute of India (IN), Pfizer (US), Haffkine Bio-Pharmaceutical Corporation (IN), Zydus Cadila (IN) are some of the major participants in the global market. **Report ID:** MRFR/Pharma/28928-HCR · **Pages:** 100 · **Author:** Rahul Gotadki · **Last Updated:** April 22, 2026 **URL:** https://www.marketresearchfuture.com/reports/human-rabies-vaccine-market-30685 --- ## Market Summary ## **Human Rabies Vaccine Market Overview** As per MRFR analysis, the Human Rabies Vaccine Market Size was estimated at 0.62 (USD Billion) in 2024. The Human Rabies Vaccine Market Industry is expected to grow from 0.67 (USD Billion) in 2025 to 1.23 (USD Billion) till 2034, at a CAGR (growth rate) is expected to be around 6.98% during the forecast period (2025 - 2034). ### **Key Human Rabies Vaccine Market Trends Highlighted** Globally, the human rabies vaccine market exhibits promising growth prospects. Key market drivers include increasing awareness about rabies prevention and vaccination, expanding immunization programs in developing regions, and the rise in animal-borne diseases. Governments and non-profit organizations are actively involved in promoting rabies awareness campaigns, which has contributed to the increased demand for vaccines. Additionally, technological advancements, such as the development of new vaccine formulations and delivery methods, are creating opportunities for market growth. In recent times, trends in the human rabies vaccine market include the emergence of needle-free vaccination systems, advancements in vaccine storage and transportation, and the rising focus on personalized vaccination approaches tailored to specific population groups. The market is expected to witness continued growth in the coming years due to these factors, providing opportunities for manufacturers and suppliers to expand their offerings and cater to the evolving needs of the market. Source: Primary Research, Secondary Research, MRFR Database and Analyst Review ## **Human Rabies Vaccine Market Drivers** ### **Increasing Incidence of Rabies** Rabies is a fatal viral disease that affects the central nervous system. It is transmitted through the bite of an infected animal, most commonly dogs. The World Health Organization (WHO) estimates that rabies causes approximately 59,000 deaths each year, primarily in Asia and Africa. The increasing incidence of rabies is a major driver of the Human Rabies Vaccine Market. The rising number of rabies cases is due to several factors, including the growing population of stray dogs, the lack of access to rabies vaccination in some regions, and the increasing movement of people and animals across borders. As the incidence of rabies continues to rise, the demand for human rabies vaccines is expected to grow. ### **Growing Awareness of Rabies Prevention** The growing awareness of rabies prevention is another major driver of the Human Rabies Vaccine Market. Public health campaigns and educational programs have helped to raise awareness of the importance of rabies vaccination. As more people become aware of the risks of rabies and the benefits of vaccination, the demand for human rabies vaccines is expected to increase. The Human Rabies Vaccine Market Industry includes key players such as Sanofi Pasteur, Merck & Co., Inc., and GSK. ### **Government Initiatives to Control Rabies** Government initiatives to control rabies are also driving the growth of the Human Rabies Vaccine Market. Many governments have implemented mandatory rabies vaccination programs for dogs and other animals. These programs have helped to reduce the incidence of rabies in some regions. However, rabies remains a major problem in many developing countries, where access to rabies vaccination is limited. As governments continue to implement rabies control programs, the demand for human rabies vaccines is expected to increase in these regions. ## **Human Rabies Vaccine Market Segment Insights** ### **Human Rabies Vaccine Market Vaccine Type Insights** The market is segmented based on vaccine type into killed virus vaccine, modified live virus vaccine, and recombinant vaccine. Killed Virus Vaccine: Killed virus vaccines are produced by inactivating the rabies virus using chemicals or heat. They are the most commonly used type of rabies vaccine and are highly effective in preventing the disease. Killed virus vaccines are generally well-tolerated and have a low risk of side effects. Modified Live Virus Vaccine: Modified live virus vaccines are produced by weakening the rabies virus in the laboratory. They are less commonly used than killed virus vaccines but are generally more effective in preventing rabies. Modified live virus vaccines can cause more side effects than killed virus vaccines, but these side effects are usually mild. Recombinant Vaccine: Recombinant vaccines are produced using genetic engineering techniques. They are the newest type of rabies vaccine and are highly effective in preventing the disease. Recombinant vaccines are generally well-tolerated and have a low risk of side effects. The killed virus vaccine segment held the largest share of the Human Rabies Vaccine Market in 2023 due to its widespread use and high efficacy. However, the modified live virus vaccine segment is expected to grow at a faster CAGR during the forecast period due to its increased effectiveness and lower risk of side effects. The recombinant vaccine segment is also expected to grow at a significant CAGR during the forecast period due to its high efficacy and low risk of side effects. Overall, the Human Rabies Vaccine Market is expected to grow at a steady pace during the forecast period, driven by the increasing demand for rabies vaccines in developing countries and the development of new and more effective vaccines. Source: Primary Research, Secondary Research, MRFR Database and Analyst Review ### **Human Rabies Vaccine Market Route of Administration Insights** #### **Intramuscular Injection** Intramuscular Injection accounted for the largest revenue share in 2023. Intramuscular Injection is the most common route of administration for rabies vaccines. It is a safe and effective way to deliver the vaccine to the body. The vaccine is injected into the muscle, where it is absorbed into the bloodstream. #### **Intradermal Injection** Intradermal Injection is another common route of administration for rabies vaccines. It is less painful than intramuscular injection, but it is not as effective. The vaccine is injected into the skin, where it is absorbed into the bloodstream. #### **Subcutaneous Injection** Subcutaneous Injection is the least common route of administration for rabies vaccines. It is less painful than intramuscular injection, but it is not as effective. The vaccine is injected under the skin, where it is absorbed into the bloodstream. ### **Human Rabies Vaccine Market Immunoglobulins Insights** Immunoglobulins, comprising Human Rabies Immunoglobulin (HRIG) and Equine Rabies Immunoglobulin (ERIG), play a crucial role in the Human Rabies Vaccine Market. HRIG, derived from human plasma, offers high potency and a low risk of allergic reactions. ERIG, obtained from horse serum, is a more cost-effective option. In 2023, the Immunoglobulins segment held a significant market share, valued at approximately USD 0.29 billion. It is projected to grow at a CAGR of 6.98%, reaching an estimated USD 0.51 billion by 2032. The rising incidence of rabies, particularly in developing countries, coupled with increased awareness and vaccination programs, is driving market growth. Additionally, the development of new and improved immunoglobulin formulations is expected to further boost segment expansion ### **Human Rabies Vaccine Market Application Insights** The Human Rabies Vaccine Market size for Pre-Exposure Prophylaxis is expected to grow from an estimated USD 0.36 billion in 2023 to USD 0.58 billion by 2032, at a CAGR of 6.1%. The Human Rabies Vaccine Market size for Post-Exposure Prophylaxis is expected to grow from USD 0.19 billion in 2023 to USD 0.43 billion by 2032, at a CAGR of 7.6%. The market growth is attributed to the increasing incidence of rabies, the rising awareness of rabies prevention, and the availability of effective vaccines. The Pre-Exposure Prophylaxis segment is expected to hold a larger market share due to the increasing adoption of pre-exposure vaccination among travelers, healthcare workers, and individuals living in endemic areas. The Post-Exposure Prophylaxis segment is expected to experience significant growth due to the rising incidence of animal bites and the need for immediate post-exposure treatment. ### **Human Rabies Vaccine Market Dosage Form Insights** The Human Rabies Vaccine Market is segmented by Dosage Form into Vials and Pre-Filled Syringes. Among these, the Vials segment held a larger market share in 2023, owing to the widespread availability and ease of administration of vials in various healthcare settings. However, the Pre-Filled Syringes segment is anticipated to exhibit a higher growth rate during the forecast period. The growing adoption of pre-filled syringes for subcutaneous administration and the increasing convenience they offer in terms of accurate dosing and ease of handling are driving the growth of this segment. In 2023, the Human Rabies Vaccine Market for Vials was valued at 0.31 USD Billion, and it is projected to reach 0.49 USD Billion by 2032, exhibiting a CAGR of 6.04%. The Pre-Filled Syringes segment, valued at 0.24 USD Billion in 2023, is estimated to reach 0.52 USD Billion by 2032, growing at a CAGR of 8.37%. ### **Human Rabies Vaccine Market Regional Insights** North America dominated the market share in 2023, owing to the presence of a well-established healthcare infrastructure, a high incidence of rabies cases, and favorable government initiatives for rabies prevention and control. Europe is projected to experience steady growth due to increasing awareness about rabies and government initiatives to eliminate the disease. APAC is expected to witness the fastest growth, driven by rising healthcare expenditure, growing population, and increasing urbanization. South America and MEA are anticipated to contribute significantly to the market growth due to rising disposable income and improving healthcare access. Source: Primary Research, Secondary Research, MRFR Database and Analyst Review ## **Human Rabies Vaccine Market Key Players and Competitive Insights** Major players in the Human Rabies Vaccine Market industry are constantly involved in R&D activities to develop innovative and more effective vaccines. Leading Human Rabies Vaccine Market players are focused on expanding their product portfolio through strategic collaborations, partnerships, and acquisitions. The Human Rabies Vaccine Market is highly competitive, with several key players accounting for a significant market share. These players are investing heavily in research and development to develop more advanced and effective vaccines. They are also expanding their geographic reach through strategic partnerships and collaborations. Sanofi Pasteur, a leading company in the Human Rabies Vaccine Market, is committed to providing innovative and high-quality vaccines to prevent rabies. The company's rabies vaccine, RabAvert, is a highly effective vaccine that has been used to protect millions of people worldwide. Sanofi Pasteur is also actively involved in research and development to develop new and improved rabies vaccines. Another key player in the Human Rabies Vaccine Market is Bavarian Nordic. The company's rabies vaccine, Rabipur, is a well-established and widely used vaccine that has been shown to be safe and effective. Bavarian Nordic is also developing a next-generation rabies vaccine that is expected to provide even better protection against the virus. ### **Key Companies in the Human Rabies Vaccine Market Include** - Biofabri - Serum Institute of India Ltd - Sanofi Pasteur - Incepta Vaccine - Hunan Changde BioPharmaceutical - Bharat Biotech International Ltd - GSK - Bavarian Nordic - [Pfizer](https://www.pfizer.com/products/product-list) - Pasteur Institute of Korea - Sinovac Biotech - Chengda Biopharm - Bio Farma - Abbott Laboratories - J/Merck Sharp Dohme ## **Human Rabies Vaccine Market Industry Developments** Key factors driving growth include increasing awareness of rabies prevention, expanding vaccination programs, and technological advancements in vaccine development. Recent developments include the introduction of more effective and affordable rabies vaccines, such as the vero cell rabies vaccine. Furthermore, strategic collaborations and partnerships between pharmaceutical companies and research institutions are fostering innovation and expanding market reach. Governments worldwide are prioritizing rabies control measures, leading to increased demand for human rabies vaccines. ## **Human Rabies Vaccine Market Segmentation Insights** ### **Human Rabies Vaccine Market Vaccine Type Outlook** - Killed Virus Vaccine - Modified Live Virus Vaccine - Recombinant Vaccine ### **Human Rabies Vaccine Market Route of Administration Outlook** - Intramuscular Injection - Intradermal Injection - Subcutaneous Injection ### **Human Rabies Vaccine Market Immunoglobulins Outlook** - Human Rabies Immunoglobulin (HRIG) - Equine Rabies Immunoglobulin (ERIG) ### **Human Rabies Vaccine Market Application Outlook** - Pre-Exposure Prophylaxis - Post-Exposure Prophylaxis ### **Human Rabies Vaccine Market Dosage Form Outlook** - Vials - Pre-Filled Syringes ### **Human Rabies Vaccine Market Regional Outlook** - North America - Europe - South America - Asia Pacific - Middle East and Africa ## Market Drivers ### 增加旅行和移民 国际旅行和移民的增加可能会影响人用狂犬病疫苗市场。随着人们前往狂犬病流行的地区，暴露风险增加，促使旅行者在出行前寻求接种疫苗。这一趋势在冒险旅行者和可能接触野生动物或流浪动物的外籍人士中尤为明显。因此，预防性狂犬病疫苗接种的需求预计将上升，推动市场增长。此外，随着移民模式的变化，公共卫生当局可能会实施疫苗接种计划，以保护脆弱人群，进一步促进人用狂犬病疫苗市场的扩展。 ### 政府倡议和资金 旨在消灭狂犬病的政府举措可能会显著影响人用狂犬病疫苗市场。各国已实施国家狂犬病控制计划，这些计划通常包括对人类和动物的疫苗接种策略。例如，泛美卫生组织报告称，拉丁美洲的狂犬病疫苗接种活动得到了大量投资。这些举措不仅提升了公共卫生，还为疫苗制造商创造了良好的环境。对狂犬病预防项目的资金增加可能会导致疫苗获取的扩大，从而推动市场增长。此外，政府与非政府组织之间的合作可以促进在服务不足地区的疫苗分发，进一步增强人用狂犬病疫苗市场。 ### 狂犬病病例上升 狂犬病病例在各个地区的日益增加似乎是人用狂犬病疫苗市场的主要驱动因素。根据世界卫生组织的数据，狂犬病每年导致约59,000人死亡，主要发生在发展中国家。这个令人震惊的统计数据突显了有效疫苗接种计划的迫切需求。随着人们对通过动物咬伤传播狂犬病的认识不断提高，公共卫生倡议可能会强调疫苗接种作为预防措施。因此，对狂犬病控制的高度关注可能会导致人用狂犬病疫苗的需求增加，从而推动市场增长。此外，某些地区狂犬病的发病率上升可能促使政府和卫生组织分配更多资源用于疫苗接种活动，进一步刺激人用狂犬病疫苗市场。 ### 发展兽医疫苗接种计划 兽医疫苗接种计划的扩展预计将对人用狂犬疫苗市场产生积极影响。随着宠物拥有率的增加和对人畜共患病意识的提高，越来越多的宠物主人可能会为他们的动物接种狂犬疫苗。这种主动的做法不仅保护了宠物，还减少了狂犬病传播给人类的风险。因此，随着社区认识到群体免疫的重要性，人用狂犬疫苗的需求可能会增加。此外，兽医和人类健康部门之间的合作可以增强疫苗接种工作，产生协同效应，从而使人用狂犬疫苗市场受益。 ### 疫苗生产中的技术创新 疫苗生产的技术进步有望改变人类狂犬病疫苗市场。重组DNA技术和改进的佐剂等创新有潜力提高疫苗的有效性和安全性。这些进展可能导致开发出更有效的疫苗，所需剂量更少，从而提高患者的依从性。此外，更高效的疫苗生产能力可能降低成本，使其更易于接触到高风险人群。随着制造商采用这些尖端技术，人类狂犬病疫苗市场可能会出现产品供应的激增，以满足多样化的消费者需求和偏好。 ## Future Outlook 人用狂犬病疫苗市场预计将在2024年至2035年间以6.98%的年复合增长率增长，推动因素包括意识的提高、狂犬病发病率的上升以及疫苗技术的进步。 **New opportunities:** - 扩大疫苗咨询的远程医疗服务 开发组合疫苗以实现更广泛的疾病预防 与兽医服务合作开展社区疫苗接种项目 到2035年，市场预计将实现强劲增长，巩固其在全球健康中的地位。 ## Segment Insights ### 按类型：灭活病毒疫苗（最大）与重组疫苗（增长最快） 在人用狂犬病疫苗市场中，灭活病毒疫苗目前在各种类型中占据最大的市场份额。这种经典疫苗因其长期有效性和在人类及兽医应用中的广泛接受而确立了其主导地位。改良活病毒疫苗也占有相当大的市场份额，但其份额正逐渐被对重组疫苗日益增长的偏好所取代。市场分析师注意到，狂犬病预防方面正在向结合安全性和有效性的创新解决方案转变。人用狂犬病疫苗市场的增长趋势主要受到对狂犬病预防意识提高和疫苗技术进步的推动。特别是重组疫苗，随着消费者和医疗服务提供者寻求更安全、更有效的疫苗接种选项，正在迅速崛起。随着对减少不良反应的关注，同时保持高效能，重组疫苗的趋势表明了医疗行业向创新和以患者为中心的解决方案的更大运动。 疫苗类型：灭活病毒（主导）与重组疫苗（新兴） 灭活病毒疫苗被认为是人类狂犬病疫苗市场的主导部分，因为它具有良好的安全性和有效性记录。它通常由已被杀死或灭活的病毒颗粒制成，这使其无法引起疾病，同时仍能引发强烈的免疫反应。这种类型的疫苗因其在狂犬病预防中的可靠性而受到青睐，特别是在动物和人类接触狂犬病的情况下。另一方面，重组疫苗代表了新兴领域，展示了生物技术进步带来的创新。它们被设计用于产生狂犬病毒的特定抗原，从而降低不良反应的可能性并改善免疫反应。向重组疫苗的转变表明市场正在发展，以应对现代健康挑战和消费者期望。 ### 按给药途径：肌肉注射（最大）与皮内注射（增长最快） 在人用狂犬病疫苗市场中，各种给药途径的市场份额分布显示，肌肉注射占据了最大的份额，这得益于其长期以来的接受度和在疫苗投递中的有效性。紧随其后，皮内注射在新兴市场中逐渐受到关注，因为它在降低剂量需求和提高患者舒适度方面具有潜力。皮下注射虽然也相关，但占据的份额较小，并且面临着与其他方法相比影响其采用的独特挑战。 给药方法：肌肉注射（主流）与皮内注射（新兴） 肌肉注射仍然是人用狂犬疫苗市场的主要给药方式，因为其已建立的疗效、易于施用以及在各种医疗环境中的广泛接受度。然而，皮内注射正在强劲崛起，因其优势如需要更小的疫苗量和增强免疫反应而受到认可。随着医疗提供者越来越寻求优化疫苗分发和患者体验，这种方法的吸引力不断增加，特别是在资源有限的地区。皮内技术的灵活性和创新应用正在激发兴趣和投资，可能重塑市场格局。 ### 通过免疫球蛋白：HRIG（最大）与ERIG（增长最快） 在人用狂犬病疫苗市场中，免疫球蛋白类型的分布显示出人用狂犬病免疫球蛋白（HRIG）的明显主导地位，它占据了市场份额的相当大一部分。该细分市场已建立并广泛认可，因其在狂犬病暴露后预防中的有效性而受到重视。同时，虽然马用狂犬病免疫球蛋白（ERIG）的使用不如HRIG广泛，但由于其成本效益和某些临床应用等因素，正在特定人群中逐渐获得认可并推动其采用。 免疫球蛋白：HRIG（主导）与ERIG（新兴） 人用狂犬病免疫球蛋白（HRIG）在免疫球蛋白领域中仍然是主导者，因为其已建立的安全性和有效性，使其成为暴露后狂犬病治疗的首选。HRIG 来源于人类血浆，提供了较低的过敏反应风险，并增强了患者的安全性。另一方面，马用狂犬病免疫球蛋白（ERIG）正在市场上崭露头角，吸引寻求经济实惠替代方案的医疗服务提供者。尽管 ERIG 可能带来更高的不良反应风险，但其经济性和在特定情况下的有效性促成了其日益被接受，特别是在资源有限的地区。 ### 按应用：暴露后预防（最大）与暴露前预防（增长最快） 在人用狂犬病疫苗市场中，应用细分主要分为两类：暴露前预防和暴露后预防。暴露后预防细分占据了最大的市场份额，因其在管理潜在狂犬病动物暴露后的狂犬病感染中发挥着关键作用。另一方面，暴露前预防因在高风险地区日益增强的意识和疫苗接种活动而获得关注，促进了其市场份额的增长。 应用：暴露后预防（主导）与暴露前预防（新兴） 暴露后预防（PEP）被认为是人用狂犬病疫苗市场的主要应用，主要用于在潜在狂犬病暴露后进行有效的疾病预防。该细分市场受益于强有力的医疗保健协议和公共卫生倡议，强调及时接种疫苗。相反，暴露前预防（PrEP）正在迅速崛起，受到对地方性地区狂犬病威胁意识提高的推动，以及旅行者和高风险专业人士采取的主动措施。PEP作为一种反应措施，而PrEP则侧重于预防，形成了市场增长中的动态互动，因为这两个细分市场满足了不同但重叠的人口需求。 ### 按剂型：瓶（最大）与预填充注射器（增长最快） 人用狂犬病疫苗市场主要由小瓶驱动，目前在该细分市场中占据最大份额。小瓶因其在疫苗投递中的传统使用而受到青睐，并在医疗界广泛接受。它们的既定存在确保了稳定的需求，并在全球各地的市场中占据了强大的立足点。相比之下，预填充注射器虽然代表了较小的市场份额，但由于其便利性和易于管理，正在迅速获得关注，特别是在优先考虑快速反应时间的环境中。人用狂犬病疫苗市场的增长趋势表明，医疗提供者正在寻求高效的疫苗接种方法，预填充注射器的便利性减少了准备时间并降低了污染风险，这与旨在提高疫苗接种率的公共卫生倡议相一致。此外，注射器技术的进步以及对狂犬病预防意识的提高正在推动对这些新兴剂型的需求，使其成为未来狂犬病疫苗接种策略的重要组成部分。 小瓶（主导）与预填充注射器（新兴） 小瓶长期以来一直是人用狂犬病疫苗市场的主导剂型，提供了可靠的储存和便于医疗提供者使用的特点。它们通常设计为多剂量，这不仅有助于资源优化，还为疫苗接种计划提供了灵活性。然而，预填充注射器的出现值得注意；由于其预先测量的剂量和降低感染风险等特性，这些注射器正日益受到欢迎。它们的设计确保疫苗更高效地接种，使得在疫苗接种活动中能够更快地响应。因此，尽管小瓶仍然至关重要，但预填充注射器代表了狂犬病疫苗接种的未来，将可及性和简化的管理作为市场演变的驱动因素。 ## Regional Market Share Analysis ### 北美：疫苗的主要市场 北美是人用狂犬病疫苗最大的市场，占全球市场份额的约40%。该地区的增长受到对狂犬病预防意识提高、严格的监管框架和强大的医疗基础设施的推动。对狂犬病疫苗的需求进一步受到宠物拥有率上升和野生动物中狂犬病流行的推动，促使公共卫生倡议推广疫苗接种。美国和加拿大是该地区的主要国家，默克公司和辉瑞等主要制药公司积极参与疫苗生产。竞争格局以创新和关键参与者之间的战略合作为特征，确保有效疫苗的稳定供应。先进的研究设施和疫苗开发资金的存在也促进了该地区在市场中的主导地位。 ### 欧洲：监管框架推动增长 欧洲的人用狂犬病疫苗市场正在经历显著增长，占全球市场份额的约30%。该地区受益于强有力的监管支持和旨在预防狂犬病的公共卫生倡议。德国和法国等国处于前沿，日益增加的疫苗接种活动和宣传项目促进了市场扩展。欧洲药品管理局（EMA）在确保疫苗安全性和有效性方面发挥了关键作用，进一步增强了消费者信心。欧洲的主要国家包括德国、法国和英国，圣诺菲和葛兰素史克等主要参与者积极参与疫苗开发。竞争格局以公共卫生组织与私营公司之间的合作为特征，增强了疫苗的可及性。先进的医疗系统和对研究项目的资金支持也促进了该地区狂犬病疫苗市场的增长。 ### 亚太地区：新兴市场潜力 亚太地区正在成为人用狂犬病疫苗的重要市场，占全球市场份额的约25%。该地区的增长受到狂犬病发生率上升的推动，特别是在印度和中国等国，公共卫生运动正在加大力度。监管机构也在关注改善疫苗的可及性和可负担性，这对控制人口密集地区的狂犬病疫情至关重要。印度和中国是该地区的主要国家，巴拉特生物技术公司和印度血清研究所等关键参与者在疫苗生产中做出了重要贡献。竞争格局正在演变，本地制造商正在增加市场份额。政府机构与私营部门之间的合作正在促进创新，并确保稳定的疫苗供应以满足该地区日益增长的需求。 ### 中东和非洲：挑战与机遇 中东和非洲地区对人用狂犬病疫苗的需求日益增长，占全球市场份额的约5%。特别是在农村地区，狂犬病病例的增加推动了对有效疫苗接种计划的需求。监管挑战和有限的医疗基础设施构成了重大障碍，但世界卫生组织等组织的倡议正在改善疫苗分发和意识。南非和尼日利亚等国在狂犬病疫苗接种工作中处于前沿，当地制造商与国际组织合作以提高疫苗的可用性。竞争格局以本地和全球参与者的混合为特征，重点是增加公共卫生倡议。该地区独特的挑战为狂犬病疫苗开发的创新和投资提供了机会。 ## Competitive Benchmarking 人用狂犬病疫苗市场的竞争格局日益受到创新、战略合作和区域扩展的影响。主要参与者如赛诺菲（法国）、默克公司（美国）和印度血清研究所（印度）处于市场前沿，各自采取不同的策略以增强市场存在感。赛诺菲（法国）专注于利用其广泛的研究能力开发下一代疫苗，而默克公司（美国）则强调与地方卫生当局的战略合作，以改善疫苗的可及性。另一方面，印度血清研究所（印度）则专注于扩大生产，以满足日益增长的全球需求，特别是在新兴市场。这些策略共同促进了一个动态的竞争环境，其中创新和可及性至关重要。 在商业策略方面，各公司越来越多地本地化生产，以降低成本并提高供应链效率。这种方法在狂犬病发病率高的地区特别有效，因为本地生产可以显著降低分销挑战。市场结构适度分散，多个参与者争夺市场份额，但主要公司的影响力仍然很大。他们优化供应链和本地化生产的能力可能会在未来几年内塑造竞争动态。 2025年8月，默克公司（美国）宣布与一家领先的非营利组织建立合作伙伴关系，以增强非洲农村地区的狂犬病疫苗接种活动。这一战略举措意义重大，因为它不仅扩大了默克在服务不足市场的覆盖面，还与全球健康倡议相一致，旨在消灭狂犬病。通过与地方组织合作，默克可能会改善疫苗的分发和宣传，从而提升其品牌声誉和市场份额。 2025年9月，赛诺菲（法国）推出了一种新的狂犬病疫苗配方，承诺减少有效免疫所需的剂量。这一创新至关重要，因为它解决了疫苗接种中的后勤挑战，特别是在偏远地区。这种配方的推出可能会导致疫苗接种率的提高，使赛诺菲在狂犬病预防工作中处于领先地位。 2025年7月，印度血清研究所（印度）将其生产能力扩大了30%，以满足对狂犬病疫苗日益增长的全球需求。这一扩张表明该公司致力于满足公共卫生需求，并可能增强其在市场上的竞争优势。通过提高生产能力，印度血清研究所可能会巩固其在国内和国际市场上的关键供应商地位。 截至2025年10月，人用狂犬病疫苗市场正在见证强调数字化、可持续性和先进技术整合的趋势。各公司越来越多地形成战略联盟，以增强其运营能力和市场覆盖面。竞争格局正在从以价格为基础的竞争转向优先考虑创新、技术进步和供应链可靠性。这一演变表明，未来的差异化将取决于提供高质量、可及疫苗的能力，同时保持运营效率。 ## Recent News & Developments 推动增长的关键因素包括对狂犬病预防意识的提高、疫苗接种计划的扩展以及疫苗开发技术的进步。最近的发展包括推出更有效且更实惠的狂犬病疫苗，如vero细胞狂犬病疫苗。 此外，制药公司与研究机构之间的战略合作与伙伴关系正在促进创新并扩大市场覆盖面。全球各国政府正在优先考虑狂犬病控制措施，导致对人用狂犬病疫苗的需求增加。 ## Report Scope | 2024年市场规模 | 0.6245（十亿美元） | | --- | --- | | 2025年市场规模 | 0.6681（十亿美元） | | 2035年市场规模 | 1.312（十亿美元） | | 复合年增长率（CAGR） | 6.98%（2024 - 2035） | | 报告覆盖范围 | 收入预测、竞争格局、增长因素和趋势 | | 基准年 | 2024 | | 市场预测期 | 2025 - 2035 | | 历史数据 | 2019 - 2024 | | 市场预测单位 | 十亿美元 | | 关键公司简介 | 市场分析进行中 | | 覆盖的细分市场 | 市场细分分析进行中 | | 关键市场机会 | 疫苗输送系统的进步提高了人用狂犬疫苗市场的可及性。 | | 关键市场动态 | 对预防性医疗的需求上升推动了人用狂犬疫苗市场的创新和竞争。 | | 覆盖的国家 | 北美、欧洲、亚太、南美、中东和非洲 | ## Frequently Asked Questions **Q: 截至2024年，人用狂犬病疫苗市场的当前估值是多少？** A: 人用狂犬病疫苗市场在2024年的估值为6.245亿美元。 **Q: 2035年人狂犬病疫苗市场的预计市场估值是多少？** A: 预计到2035年，市场将达到13.12亿美元。 **Q: 在2025年至2035年的预测期内，人用狂犬病疫苗市场的预期CAGR是多少？** A: 预计市场在预测期内的年均增长率（CAGR）为6.98%。 **Q: 在狂犬病疫苗市场中，哪些公司被视为关键参与者？** A: 主要参与者包括赛诺菲、巴拉特生物技术、默克公司、葛兰素史克、印度血清研究所、辉瑞、哈夫金生物制药公司和Zydus Cadila。 **Q: 人狂犬疫苗市场上有哪些不同类型的疫苗？** A: 市场包括灭活病毒疫苗、减毒活病毒疫苗和重组疫苗。 **Q: 给药途径的市场细分是如何划分的？** A: 给药途径部分包括肌肉注射、皮内注射和皮下注射。 **Q: 人用狂犬病疫苗市场上有哪些免疫球蛋白类型？** A: 市场上有人用狂犬病免疫球蛋白（HRIG）和马用狂犬病免疫球蛋白（ERIG）。 **Q: 人用狂犬病疫苗市场涵盖了哪些应用？** A: 应用包括暴露前预防和暴露后预防。 **Q: 人用狂犬病疫苗市场有哪些剂型可供选择？** A: 市场提供小瓶和预填充注射器作为剂型。 **Q: 2024年灭活病毒疫苗部门的估值是多少？** A: 2024年，灭活病毒疫苗细分市场的价值为3.747亿美元。 --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/human-rabies-vaccine-market-30685*